Preclinical studies show Aqualung Therapeutic’s eNAMPT- targeting ALT-100 mAb to reduce severity of aggressive prostate cancer

Preclinical prostate cancer (PCa] studies published in the December 17th, 2021 issue of Pharmaceuticals show Aqualung Therapeutic’s ALT-100 mAb to significantly improve overall survival and to reduce distal metastases in SCID mice implanted with human prostate cancer (PCa] cells. Aqualung Therapeutics is an early stage immunotherapeutics company with an anti-inflammatory therapeutic platform to address life-threatening unchecked inflammation.

Continue reading

UACI Sponsorship Launch Program – Apply Today

Through collaboration and sponsorship with Perkins Coie LLP, UACI is offering a sponsored year at the incubator for one deserving startup with a committed team that is working to solve a significant business or social challenge. The winning team will also receive a cash award of $15,000, which includes funding for a legal project budget. The total prize package is valued at $25,000.

Continue reading

HybridChart Partners with athenahealth’s Marketplace Program to Bring Workflow Efficiency Solution to Rounding Physicians

Scottsdale, AZ – September 23, 2021 – HybridChart, a leading solutions provider for charge capture and workflow management, announced a partnership with athenahealth, Inc. joining the company’s Marketplace program. As part of the athenahealth® Marketplace, the EVOLVE product by HybridChart is a newly integrated application now available to athenahealth’s growing network of healthcare providers.Continue reading

Nationwide study of 295,000 brain cancer patients examines differences due to age and sex

Study by TGen and collaborators documents different outcomes for males and females at various ages

PHOENIX, Ariz. — Sept. 22, 2021 — Findings from a national study by researchers at Translational Genomics Research Institute (TGen), an affiliate of City of Hope, and external collaborators suggest that sex and age are crucial factors in the care and survival of patients with malignant brain tumors and other central nervous system (CNS) cancers.

Continue reading

Startup with an Innovative Imaging System Wins Sponsorship at The University of Arizona Center for Innovation Fueled by Concord General Contracting

TUCSON, Ariz.– The University of Arizona Center for Innovation (UACI) is pleased to announce that QScint Imaging Solutions, LLC. has won the UACI Sponsored Launch Fueled by Concord General Contracting competition.

QScint Imaging Solutions, LLC. manufactures iQID charged-particle digital autoradiography imaging systems for use in radiopharmaceutical drug development, geological studies, and nuclear forensics applications.

Continue reading

FDA clears the CATS®-D Disposable Tonometer Prism.

The FDA has cleared the CATS®-D Disposable Tonometer Prism for sale in the United States, assuring that eye care clinicians have accurate intraocular pressure (IOP) measurement data — a key metric — for the diagnosis and treatment of glaucoma and other serious ocular conditions.

The patented CATS®-D Tonometer Prism is designed to deliver improved IOP measurement accuracy with a sterile, disposable tip replacement for the Goldmann tonometer.

Continue reading

TGen-led study of more than 70,000 individuals links dementia to smoking and cardiovascular disease 

Significantly, women impaired more by smoking; men impaired more by cardiovascular disease

PHOENIX, Ariz. — May 13, 2021 — In the largest study of the associations between smoking and cardiovascular disease on cognitive function, researchers at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, found both impair the ability to learn and memorize; and that the effects of smoking are more pronounced among females, while males are more impaired by cardiovascular disease.

Continue reading